To show whether addition of thrombolytic treatment by a single bolus injection of tenecteplase prior to early standard PCI (percutaneous coronary intervention) will improve the clinical outcome in patients with large acute myocardial infarcts as compared to primary PCI alone.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1,671
Boehringer Ingelheim Investigational Site
Little Rock, Arkansas, United States
Boehringer Ingelheim Investigational Site
Fort Lauderdale, Florida, United States
Boehringer Ingelheim Investigational Site
St. Petersburg, Florida, United States
Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
Boehringer Ingelheim Investigational Site
Macan, Georgia, United States
Death or cardiogenic shock or congestive heart failure within 90 days
Time frame: 90 days
Death or cardiogenic shock or congestive heart failure within 30 days
Time frame: 30 days
Cardiogenic shock or congestive heart failure within 90 days
Time frame: 90 days
Death
Time frame: 90 days
Cardiogenic shock
Time frame: 90 days
Reinfarction
Time frame: 90 days
Repeat target vessel revascularisation (TVR)
Time frame: 90 days
Rehospitalisation for congestive heart failure
Time frame: 90 days
Rehospitalisation for cardiogenic shock
Time frame: 90 days
Rehospitalisation for other cardiac reasons
Time frame: 90 days
Congestive heart failure
Time frame: 90 days
N-terminal pro-brain natriuretic peptide (NT pro-BNP)
Time frame: 90 days
Disabling stroke
Time frame: 90 days
Total stroke
Time frame: 90 days
Rehospitalisation for stroke or ICH (intrancranial haemorrhage)
Time frame: 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Boehringer Ingelheim Investigational Site
Detroit, Michigan, United States
Boehringer Ingelheim Investigational Site
Omaha, Nebraska, United States
Boehringer Ingelheim Investigational Site
Providence, Rhode Island, United States
Boehringer Ingelheim Investigational Site
Feldkirch, Austria
Boehringer Ingelheim Investigational Site
Sankt Pölten, Austria
...and 166 more locations